Verve Therapeutics Q3 EPS $(0.72) Beats $(0.92) Estimate, Sales $3.12M May Not Be Comparable To $960.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Verve Therapeutics reported Q3 losses of $(0.72) per share, beating the analyst consensus estimate of $(0.92) by 21.74%. This is an 8.86% increase over losses from the same period last year. The company also reported quarterly sales of $3.12 million, beating the analyst consensus estimate of $960.00 thousand by 224.69%, a 235.52% increase over sales from the same period last year.
November 07, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verve Therapeutics reported better than expected Q3 results with losses per share and sales both beating analyst estimates.
Verve Therapeutics reported better than expected Q3 results, with both losses per share and sales beating analyst estimates. This could lead to a positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100